Literature DB >> 28527883

Endovascular Iliocaval Stent Reconstruction for Inferior Vena Cava Filter-Associated Iliocaval Thrombosis: Approach, Technical Success, Safety, and Two-Year Outcomes in 120 Patients.

Jeffrey Forris Beecham Chick1, Alexandria Jo2, J Matthew Meadows2, Steven D Abramowitz3, Minhaj S Khaja2, Kyle J Cooper2, David M Williams2.   

Abstract

PURPOSE: To report technical success, outcomes, and patency of iliocaval stent reconstruction for inferior vena cava (IVC) filter-bearing iliocaval thrombosis.
MATERIALS AND METHODS: A total of 120 patients with 123 IVC filters and symptomatic iliocaval thrombosis underwent stent reconstruction. Mean patient age was 55 years (range, 19-88 y). Filters included 70 (57%) retrievable and 53 (43%) permanent filters. Symptoms included lower extremity swelling or pain (n = 93), ulcers (n = 8), phlegmasia (n = 7), back pain (n = 5), shortness of breath (n = 4), worsening renal function (n = 2), and stenosis identified during translumbar catheter placement (n = 1). Clinical success was defined as decrease in clinical, etiology, anatomy, and pathophysiology (CEAP) score of at least 1; resolution of presenting symptoms; or normalization of renal function in patients with juxtarenal or suprarenal thrombosis on presentation. Technical aspects of reconstruction, technical success, complications, 6-month clinical response, and 6-, 12-, and 24-month primary, primary-assisted, and secondary stent patency rates were recorded.
RESULTS: Stent reconstruction was technically successful in all 120 patients, 63 of whom (53%) underwent thrombolysis. Thirty filters (24%) were retrieved, and 93 (76%) were excluded with stent placement across the indwelling filter. Six minor and 2 major complications occurred. Clinical success was achieved in 115 patients (96%) at 6 months. Six-, 12-, and 24-month primary iliocaval stent patency rates were 96.4%, 94.8%, and 87.2%, respectively. Twenty-four month primary-assisted and secondary patency rates were 90.3% and 94.2%, respectively.
CONCLUSIONS: Iliocaval stent reconstruction is an effective treatment for filter-associated thrombosis with 100% technical success and 96% clinical success at 6 months. Technical and clinical outcomes in patients who underwent filter retrieval versus filter exclusion were similar.
Copyright © 2017 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28527883     DOI: 10.1016/j.jvir.2017.04.017

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

Review 1.  Endovascular Therapy for Lower Extremity Chronic Deep Venous Occlusive Disease: State of Practice.

Authors:  Vibhor Wadhwa; Ravi N Srinivasa; Kyle J Cooper; Anthony N Hage; Jacob J Bundy; Brooke Spencer; Venu Vadlamudi; Jeffrey Forris Beecham Chick
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

2.  Lower extremity endovenous reconstruction for symptomatic occlusive disease in pediatric patients: techniques, clinical outcomes, and long-term stent patencies.

Authors:  Joseph L McDevitt; Ravi N Srinivasa; Anthony N Hage; Jacob J Bundy; Joseph J Gemmete; Jeffrey Forris Beecham Chick
Journal:  Pediatr Radiol       Date:  2019-03-09

Review 3.  Intravascular ultrasound for endovascular precision in pediatrics.

Authors:  John J Weaver; David S Shin; Jeffrey Forris Beecham Chick; Eric J Monroe
Journal:  Pediatr Radiol       Date:  2021-10-30

4.  Iliocaval reconstruction of chronically thrombosed cylindrical inferior vena cava filters with balloon expandable covered stent-grafts.

Authors:  Mohamed Elboraey; Beau B Toskich; Andrew R Lewis; Charles A Ritchie; Gregory T Frey; Zlatko Devcic
Journal:  J Vasc Surg Cases Innov Tech       Date:  2021-05-21

5.  Stent Placement Across the Renal Vein Inflow in Patients Undergoing Venous Reconstruction Preserves Renal Function and Renal Vein Patency: Experience in 93 Patients.

Authors:  Jeffrey Forris Beecham Chick; Joseph J Gemmete; Anthony N Hage; Jacob J Bundy; Charles Brewerton; Jordan B Fenlon; Steven D Abramowitz; Dawn M Coleman; Ravi N Srinivasa; David M Williams
Journal:  J Endovasc Ther       Date:  2019-01-25       Impact factor: 3.487

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.